2-Pyridinecarbonitrile, 5-[5-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-3-(trifluoromethyl)-

JNJ-pan-AR, a meylated analogue of JNJ-63576253, is a novel pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. JNJ63576253, also known as TRC253, is a potent and orally active androgen receptor antagonist. TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus.